Published in Biochem Pharmacol on January 15, 1987
Drug resistance in leishmaniasis. Clin Microbiol Rev (2006) 7.35
Axenically cultured amastigote forms as an in vitro model for investigation of antileishmanial agents. Antimicrob Agents Chemother (1997) 1.83
Use of antimony in the treatment of leishmaniasis: current status and future directions. Mol Biol Int (2011) 1.71
Axenically grown amastigotes of Leishmania infantum used as an in vitro model to investigate the pentavalent antimony mode of action. Antimicrob Agents Chemother (1998) 1.44
Antimonial-mediated DNA fragmentation in Leishmania infantum amastigotes. Antimicrob Agents Chemother (2001) 1.34
Gene expression analysis of the mechanism of natural Sb(V) resistance in Leishmania donovani isolates from Nepal. Antimicrob Agents Chemother (2005) 1.34
Leishmania antimony resistance: what we know what we can learn from the field. Parasitol Res (2011) 1.22
Nitric oxide-mediated proteasome-dependent oligonucleosomal DNA fragmentation in Leishmania amazonensis amastigotes. Infect Immun (2002) 1.19
The antileishmanial agent licochalcone A interferes with the function of parasite mitochondria. Antimicrob Agents Chemother (1995) 1.10
Tolerance to drug-induced cell death favours the acquisition of multidrug resistance in Leishmania. Cell Death Dis (2011) 1.08
Resistance of Leishmania (Viannia) braziliensis to nitric oxide: correlation with antimony therapy and TNF-alpha production. BMC Infect Dis (2010) 0.97
Structures, targets and recent approaches in anti-leishmanial drug discovery and development. Open Med Chem J (2011) 0.95
Conventional therapy and promising plant-derived compounds against trypanosomatid parasites. Front Microbiol (2012) 0.88
Functional analysis of cytosolic tryparedoxin peroxidase in antimony-resistant and -susceptible Leishmania braziliensis and Leishmania infantum lines. Parasit Vectors (2014) 0.80
Experimental visceral leishmaniasis: role of trans-aconitic acid in combined chemotherapy. Antimicrob Agents Chemother (1993) 0.76
Involvement of nucleoside diphosphate kinase b and elongation factor 2 in Leishmania braziliensis antimony resistance phenotype. Parasit Vectors (2016) 0.75
New Approaches to Overcome Transport Related Drug Resistance in Trypanosomatid Parasites. Front Pharmacol (2016) 0.75
Bismuth(III) α-hydroxy carboxylates: highly selective toxicity of glycolates towards Leishmania major. J Biol Inorg Chem (2015) 0.75
Serum IgM and IgG responses in postnatally acquired rubella. Lancet (1969) 4.16
A serological method for demonstrating recent infection by rubella virus. Br Med J (1967) 4.07
Serological assessment of rubella during pregnancy. Br Med J (1970) 2.37
Multiplication of Leishmania in human macrophages in vitro. Infect Immun (1979) 2.30
Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. Am J Trop Med Hyg (1992) 2.09
Detection of rubella-specific IgM in subclinical rubella reinfection in pregnancy. Lancet (1985) 2.08
Viremia, virus excretion, and antibody responses after challenge in volunteers with low levels of antibody to rubella virus. J Infect Dis (1983) 2.07
Miltefosine for new world cutaneous leishmaniasis. Clin Infect Dis (2004) 2.02
Pancreatitis induced by pentavalent antimonial agents during treatment of leishmaniasis. Clin Infect Dis (1994) 2.02
Prevalence of antibodies to herpes simplex virus types 1 and 2 in pregnant women, and estimated rates of infection. J Epidemiol Community Health (1989) 1.92
Rubella viraemia and antibody responses after rubella vaccination and reimmunization. Lancet (1981) 1.86
In vitro susceptibility of antimony-resistant Leishmania to alternative drugs. J Infect Dis (1982) 1.83
Rubella-specific serum and nasopharygeal immunoglobulin responses following naturally acquired and vaccine-induced infection. Prolonged persistence of virus-specific IgM. Lancet (1975) 1.78
Epstein-Barr virus-specific IgM in infectious mononucleosis, Burkitt lymphoma, nasopharyngeal carcinoma. Lancet (1972) 1.73
An in vitro model for investigation of chemotherapeutic agents in leishmaniasis. J Infect Dis (1980) 1.70
Successful double-blinded, randomized, placebo-controlled field trial of azithromycin and doxycycline as prophylaxis for malaria in western Kenya. Clin Infect Dis (1998) 1.69
Rubella vaccination: persistence of antibodies for up to 16 years. Br Med J (Clin Res Ed) (1982) 1.66
Activity of imidazoles against Leishmania tropica in human macrophage cultures. Am J Trop Med Hyg (1981) 1.66
Letter: Rubella-specific IgM and a new inhibitor. Br Med J (1974) 1.66
Rubella immunity by four different techniques: results of challenge studies. J Med Virol (1980) 1.58
Studies on rubella virus strain variation by kinetic haemagglutination-inhibition tests. J Gen Virol (1970) 1.56
Placebo-controlled clinical trial of sodium stibogluconate (Pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala. J Infect Dis (1992) 1.53
In vitro antileishmanial properties of tri- and pentavalent antimonial preparations. Antimicrob Agents Chemother (1995) 1.49
PCR for detection of rubella virus RNA in clinical samples. J Clin Microbiol (1995) 1.47
Cancer associated human papillomaviruses: perinatal transmission and persistence. Br J Obstet Gynaecol (1994) 1.38
Effects of ketoconazole on sterol biosynthesis by Leishmania mexicana mexicana amastigotes in murine macrophage tumor cells. Mol Biochem Parasitol (1986) 1.37
Immunochemotherapy for intracellular Leishmania donovani infection: gamma interferon plus pentavalent antimony. J Infect Dis (1988) 1.35
Leishmania donovani: oral efficacy and toxicity of formycin B in the infected hamster. Exp Parasitol (1983) 1.34
Efficacy and toxicity of sodium stibogluconate for mucosal leishmaniasis. Ann Intern Med (1990) 1.34
Noninvasive management of Indian visceral leishmaniasis: clinical application of diagnosis by K39 antigen strip testing at a kala-azar referral unit. Clin Infect Dis (2002) 1.33
Persistence of specific IgM and low avidity specific IgG1 following primary rubella. J Virol Methods (1992) 1.32
Persistence of rubella antibody 8-18 years after vaccination. Br Med J (Clin Res Ed) (1984) 1.30
Rubella-specific serum and nasopharyngeal antibodies in volunteers with naturally acquired and vaccine-induced immunity after intranasal challenge. J Infect Dis (1980) 1.30
8-Aminoquinolines from Walter Reed Army Institute for Research for treatment and prophylaxis of Pneumocystis pneumonia in rat models. Antimicrob Agents Chemother (1991) 1.27
Maternal rubella at St Thomas' Hospital in 1978 and 1986: support for augmenting the rubella vaccination programme. Lancet (1987) 1.26
New Japanese rubella vaccine: comparative trials. Br Med J (1974) 1.26
Efficacy of ketoconazole against Leishmania braziliensis panamensis cutaneous leishmaniasis. Am J Med (1990) 1.25
In vivo and in vitro localization of Leishmania within macrophage phagolysosomes: use of colloidal gold as a lysosomal label. J Protozool (1981) 1.24
Serologic evidence of human herpesvirus 8 transmission by homosexual but not heterosexual sex. J Infect Dis (1999) 1.23
Biochemical mechanisms of the antileishmanial activity of sodium stibogluconate. Antimicrob Agents Chemother (1985) 1.22
Antileishmanial activity of liposome-encapsulated amphotericin B in hamsters and monkeys. Antimicrob Agents Chemother (1986) 1.22
A comparison of Rubazyme-M and MACRIA for the detection of rubella-specific IgM. J Virol Methods (1984) 1.21
Activity of antileishmanial agents against amastigotes in human monocyte-derived macrophages and in mouse peritoneal macrophages. J Parasitol (1984) 1.20
Successful topical treatment of murine cutaneous leishmaniasis with a combination of paromomycin (Aminosidine) and gentamicin. J Parasitol (1999) 1.19
Expression of Leishmania antigen on the surface membrane of infected human macrophages in vitro. Clin Exp Immunol (1981) 1.19
Development and persistence of class-specific antibodies in the serum and nasopharyngeal washings of rubella vaccinees. J Infect Dis (1985) 1.18
A comparison of RK-13, vervet monkey kidney and patas monkey kidney cell cultures for the isolation of rubella virus. J Hyg (Lond) (1967) 1.14
Viral infections of Toronto children during 1965: II. Measles encephalitis and other complications. Can Med Assoc J (1966) 1.12
Perinatal infection and persistence of human papillomavirus types 16 and 18 in infants. J Med Virol (1995) 1.12
Identification of immunogenic regions of the major coat protein of human papillomavirus type 16 that contain type-restricted epitopes. J Gen Virol (1989) 1.11
Once weekly azithromycin therapy for prevention of Mycobacterium avium complex infection in patients with AIDS: a randomized, double-blind, placebo-controlled multicenter trial. Clin Infect Dis (1998) 1.10
Rubella vaccines. Lancet (1979) 1.10
Susceptibility of clinically sensitive and resistant Leishmania to pentavalent antimony in vitro. Am J Trop Med Hyg (1982) 1.09
Activity of purine analogs against Leishmania tropica within human macrophages in vitro. Antimicrob Agents Chemother (1983) 1.09
Herpes simplex virus detection by ELISA: effect of enzyme amplification, nature of lesion sampled and specimen treatment. J Med Virol (1986) 1.09
Letter: Diagnosis of rubella. Br Med J (1974) 1.08
Persistence of rubella antibodies after vaccination: detection after experimental challenge. Rev Infect Dis (1985) 1.08
Effects of ketoconazole on growth and sterol biosynthesis of Leishmania mexicana promastigotes in culture. Mol Biochem Parasitol (1984) 1.06
Leishmania mexicana: uptake of sodium stibogluconate (Pentostam) and pentamidine by parasite and macrophages. Exp Parasitol (1987) 1.05
Semiautomated assessment of in vitro activity of potential antileishmanial drugs. Antimicrob Agents Chemother (1985) 1.05
Treatment of Brazilian kala-azar with a short course of amphocil (amphotericin B cholesterol dispersion). Clin Infect Dis (1993) 1.05
Rubella serology by solid-phase radioimmunoassay: its potential for screening programmes. Clin Exp Immunol (1978) 1.03
Towards vaccines against human papillomavirus type-16 genital infections. Vaccine (1993) 1.02
Use of PCR for prenatal and postnatal diagnosis of congenital rubella. J Clin Microbiol (1995) 1.01
Transmission of RA27/3 rubella vaccine strain to products of conception. Lancet (1981) 1.01
Metabolism of formycin B by Leishmania amastigotes in vitro. Comparative metabolism in infected and uninfected human macrophages. J Exp Med (1983) 1.00
Interferon response to sendai and rubella viruses in human foetal cultures, leucocytes and placental cultures. J Gen Virol (1971) 1.00
Survivability and infectivity of viscerotropic Leishmania tropica from Operation Desert Storm participants in human blood products maintained under blood bank conditions. Am J Trop Med Hyg (1993) 1.00
Molecular analysis of rubella virus epidemiology across three continents, North America, Europe, and Asia, 1961-1997. J Infect Dis (1998) 0.99
Monocyte function in human neonates. Infect Immun (1978) 0.99
Slow maturation of IgG1 avidity and persistence of specific IgM in congenital rubella: implications for diagnosis and immunopathology. J Med Virol (1993) 0.98
Fine-structural alterations in Leishmania tropica within human macrophages exposed to antileishmanial drugs in vitro. J Protozool (1983) 0.98
Analytic sensitivities of hybrid-capture, consensus and type-specific polymerase chain reactions for the detection of human papillomavirus type 16 DNA. J Med Virol (1996) 0.98
Increased frequency of the k-ras G12C mutation in MYH polyposis colorectal adenomas. Br J Cancer (2004) 0.97
Autoantigens interact with cis-acting elements of rubella virus RNA. J Virol (1996) 0.97
How well do low levels of rubella antibody protect? Lancet (1981) 0.96
Detection of E5 oncoprotein in human papillomavirus type 16-positive cervical scrapes using antibodies raised to synthetic peptides. J Gen Virol (1994) 0.96
Failure of acyclovir cream in treatment of recurrent herpes labialis. Br Med J (Clin Res Ed) (1985) 0.96
Activity of oral drugs against Leishmania tropica in human macrophages in vitro. Am J Trop Med Hyg (1983) 0.95
Interferon studies with Japanese and U.S. rubella virus strains. Br Med J (1973) 0.94
Evaluation of the 4-pyridinemethanol WR 180,409 (enpiroline) in the treatment of induced Plasmodium falciparum infections in healthy, non-immune subjects. Am J Trop Med Hyg (1984) 0.94
A cluster of cases of severe cardiotoxicity among kala-azar patients treated with a high-osmolarity lot of sodium antimony gluconate. Am J Trop Med Hyg (1998) 0.94
Growth of rubella virus in human embryonic organ cultures. J Hyg (Lond) (1968) 0.94
Rapid and complete purification of acetylcholinesterases of electric eel and erythrocyte by affinity chromatography. Proc Natl Acad Sci U S A (1971) 0.94
Rubella vaccination: persistence of antibodies for 10-21 years. Lancet (1988) 0.94
Automated rubella antibody screening:a cautionary tale. J Med Microbiol (1999) 0.93
Rubella virus infections during pregnancy, Toronto, 1963-66. Can Med Assoc J (1966) 0.93
Oral antibodies to human papillomavirus type 16 in women with cervical neoplasia. J Med Virol (2001) 0.92
Effect of temperature on multiplication of Leishmania amastigotes within human monocyte-derived macrophages in vitro. Am J Trop Med Hyg (1981) 0.92
High prevalence of human papillomavirus type 16 infection among children. J Med Virol (2000) 0.92
Proliferative T-cell responses to human papillomavirus type 16 E5 are decreased amongst women with high-grade neoplasia. J Gen Virol (1998) 0.91
Transmission of cervical cancer-associated human papilloma viruses from mother to child. Intervirology (1998) 0.91
Pharmacokinetics of pentavalent antimony (Pentostam) in hamsters. Am J Trop Med Hyg (1988) 0.91
Use of rubella virus E1 fusion proteins for detection of rubella virus antibodies. J Clin Microbiol (1995) 0.90
Congenital cytomegalovirus infection. Br Med J (Clin Res Ed) (1987) 0.90
Human papillomavirus type 16 in infants: use of DNA sequence analyses to determine the source of infection. J Gen Virol (1996) 0.90
Human herpesvirus 8: seroepidemiology among women and detection in the genital tract of seropositive women. J Infect Dis (1999) 0.90
Inhibition of growth of human leukemia cell lines by retrovirally expressed wild-type p16INK4A. Leukemia (1997) 0.90